openPR Logo
Press release

Moderate to Severe Plaque Psoriasis Pipeline Outlook 2025: Insights Into Therapies, Research, and Market Potential

09-09-2025 12:36 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Moderate to Severe Plaque Psoriasis Pipeline Outlook 2025:

DelveInsight's, "Moderate To Severe Plaque Psoriasis Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Moderate To Severe Plaque Psoriasis pipeline landscape. It covers the Moderate to Severe Plaque Psoriasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Moderate to Severe Plaque Psoriasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Moderate to Severe Plaque Psoriasis Pipeline? Click here to explore the therapies and trials making headlines @ Moderate to Severe Plaque Psoriasis Pipeline Outlook Report [https://www.delveinsight.com/sample-request/moderate-to-severe-plaque-psoriasis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Moderate to Severe Plaque Psoriasis Pipeline Report

* On 04 September 2025, Alumis Inc. announced a study following completion of one of the parent studies (ESK-001-016 or ESK-001-017) and will receive open-label ESK-001 twice daily for 24 weeks. After 24 weeks, the first 200 patients meeting at least PASI-75 clinical response will be randomly assigned to receive ESK-001 or placebo. At any point during this time, the patients losing the initial clinical response may return to the open-label ESK-001 treatment. Patients who complete Week 48 will return to open-label ESK-001 treatment and they will receive ESK-001 until the end of the study or discontinuation. All the remaining patients not meeting the entry criteria for the randomized withdrawal phase will continue to receive open-label ESK-001 for the remainder of the study.
* On 02 September 2025, Bristol-Myers Squibb conducted a study is to evaluate the efficacy, safety, and drug levels of Deucravacitinib (BMS-986165) in adolescent participants with moderate to severe plaque psoriasis.
* DelveInsight's Moderate to Severe Plaque Psoriasis Pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for Moderate to Severe Plaque Psoriasis treatment.
* The leading Moderate to Severe Plaque Psoriasis Companies such as Bristol-Myers Squibb, Akeso Biopharma, Jiangsu Hengrui Medicine, Nimbus Therapeutics, Sun Pharmaceutical Industries Limited, Suzhou Zelgen Biopharmaceuticals, GC Cell Corporation, Bioeq GmbH, Dong-A ST Co., Ltd., Can-fite Biopharma, Bio-thera Solutions, AbbVie, Sinocelltech, Jansen Research and Development, Innovent Biologics, Aurigene Discovery, Affibody, GlaxoSmithKline, Abcentra and others.
* Promising Moderate to Severe Plaque Psoriasis Therapies such as Bimekizumab, Ustekinumab, Adalimumab, KHK4827, ABT-874, Etanercept, MSB11022, CT-P17 and others.

Want to know which companies are leading innovation in Moderate to Severe Plaque Psoriasis? Dive into the full pipeline insights @ Moderate to Severe Plaque Psoriasis Clinical Trials Assessment [https://www.delveinsight.com/sample-request/moderate-to-severe-plaque-psoriasis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Moderate to Severe Plaque Psoriasis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Moderate to Severe Plaque Psoriasis Pipeline Report also highlights the unmet needs with respect to Moderate to Severe Plaque Psoriasis.

Moderate to Severe Plaque Psoriasis Overview

Moderate to Severe Plaque Psoriasis is the most common type of psoriasis. Those thick, scaly patches that develop on the skin are called plaques (placks). About 80% to 90% of people living with psoriasis get plaques, so they have plaque (plack) psoriasis. It is an autoimmune disease in which skin cells rapidly build up, forming scales and dry, itchy patches that flake off. Scientists don't yet fully understand the mechanisms behind autoimmune diseases like Moderate to Severe Plaque Psoriasis, but it is believed that a person's genetics play a central role.

Moderate to Severe Plaque Psoriasis Emerging Drugs

* BMS-986165 : Bristol-Myers Squibb

Deucravacitinib (BMS-986165) is a first-in-class, oral, selective tyrosine kinase 2 (TYK2) inhibitor with a unique mechanism of action. Deucravacitinib is the first and only TYK2 inhibitor in clinical studies across multiple immune-mediated diseases. Bristol Myers Squibb scientists designed deucravacitinib to selectively target TYK2, thereby inhibiting signaling of interleukin (IL)-12, IL-23 and Type 1 interferon (IFN), key cytokines involved in psoriasis pathogenesis. Due to the innovative design of deucravacitinib, Bristol Myers Squibb earned recognition with the 2019 Thomas Alva Edison Patent Award for the science underpinning the clinical development of deucravacitinib. Deucravacitinib is being studied in multiple immune-mediated diseases, including psoriasis, psoriatic arthritis, lupus and inflammatory bowel disease.

* AK111: Akeso Biopharma

AK111 is a novel drug targeting IL-17A of autoimmune treatment diseases independently developed by the Company. AK111 is intended to be used for the treatment of psoriasis, ankylosing spondylitis and axial spondylitis. Through combination of competitive blockers, namely IL-17A and IL-17RA, and blocking the biological activities of IL-17, AK111 has reached the efficacy in immune-related diseases in clinical therapies. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Moderate to Severe Plaque Psoriasis.

If you're tracking ongoing Moderate to Severe Plaque Psoriasis Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Moderate to Severe Plaque Psoriasis Treatment Drugs [https://www.delveinsight.com/sample-request/moderate-to-severe-plaque-psoriasis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Moderate to Severe Plaque Psoriasis Pipeline report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Moderate to Severe Plaque Psoriasis with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Moderate to Severe Plaque Psoriasis Treatment.
* Moderate to Severe Plaque Psoriasis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Moderate to Severe Plaque Psoriasis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Moderate to Severe Plaque Psoriasis market.

Moderate to Severe Plaque Psoriasis Companies

Bristol-Myers Squibb, Akeso Biopharma, Jiangsu Hengrui Medicine, Nimbus Therapeutics, Sun Pharmaceutical Industries Limited, Suzhou Zelgen Biopharmaceuticals, GC Cell Corporation, Bioeq GmbH, Dong-A ST Co., Ltd., Can-fite Biopharma, Bio-thera Solutions, AbbVie, Sinocelltech, Jansen Research and Development, Innovent Biologics, Aurigene Discovery, Affibody, GlaxoSmithKline, Abcentra and others.

Moderate to Severe Plaque Psoriasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal

Moderate to Severe Plaque Psoriasis Products have been categorized under various Molecule types such as

* Oligonucleotide
* Peptide
* Small molecule

From emerging drug candidates to competitive intelligence, the Moderate to Severe Plaque Psoriasis Pipeline Report covers it all - check it out now @ Moderate to Severe Plaque Psoriasis Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/moderate-to-severe-plaque-psoriasis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Moderate to Severe Plaque Psoriasis Pipeline Report

* Coverage- Global
* Moderate to Severe Plaque Psoriasis Companies- Bristol-Myers Squibb, Akeso Biopharma, Jiangsu Hengrui Medicine, Nimbus Therapeutics, Sun Pharmaceutical Industries Limited, Suzhou Zelgen Biopharmaceuticals, GC Cell Corporation, Bioeq GmbH, Dong-A ST Co., Ltd., Can-fite Biopharma, Bio-thera Solutions, AbbVie, Sinocelltech, Jansen Research and Development, Innovent Biologics, Aurigene Discovery, Affibody, GlaxoSmithKline, Abcentra and others.
* Moderate to Severe Plaque Psoriasis Therapies- Bimekizumab, Ustekinumab, Adalimumab, KHK4827, ABT-874, Etanercept, MSB11022, CT-P17 and others.
* Moderate to Severe Plaque Psoriasis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Moderate to Severe Plaque Psoriasis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research - discover what's next for the Moderate to Severe Plaque Psoriasis treatment landscape in this detailed analysis @ Moderate to Severe Plaque Psoriasis Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/moderate-to-severe-plaque-psoriasis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Moderate to Severe Plaque Psoriasis: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Moderate to Severe Plaque Psoriasis- DelveInsight's Analytical Perspective
* Late Stage Products (Pre-Registration)
* BMS-986165 : Bristol-Myers Squibb
* Drug profiles in the detailed report.....
* Last Stage Products (Phase III)
* Drug Name : Company Name
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* AK111: Akeso Biopharma
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name : Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Moderate to Severe Plaque Psoriasis Key Companies
* Moderate to Severe Plaque Psoriasis Key Products
* Moderate to Severe Plaque Psoriasis - Unmet Needs
* Moderate to Severe Plaque Psoriasis - Market Drivers and Barriers
* Moderate to Severe Plaque Psoriasis - Future Perspectives and Conclusion
* Moderate to Severe Plaque Psoriasis Analyst Views
* Moderate to Severe Plaque Psoriasis Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=moderate-to-severe-plaque-psoriasis-pipeline-outlook-2025-insights-into-therapies-research-and-market-potential]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/moderate-to-severe-plaque-psoriasis-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Moderate to Severe Plaque Psoriasis Pipeline Outlook 2025: Insights Into Therapies, Research, and Market Potential here

News-ID: 4174551 • Views:

More Releases from ABNewswire

Cerebral Infarction Market Dynamics: Strategic Opportunities for Pharma Companies in an Underserved Space | DelveInsight
Cerebral Infarction Market Dynamics: Strategic Opportunities for Pharma Companie …
DelveInsight reveals a market dominated by generic therapies with significant opportunities for innovation. The analysis highlights key players Pharmazz, Bayer, and Revalesio developing targeted treatments TYVALZI, BAY 3018250, and RNS60, respectively, addressing critical gaps in current cerebral infarction management across seven major markets through 2034. DelveInsight's comprehensive report titled "Cerebral Infarction Market Insights, Epidemiology, and Market Forecast - 2034 [https://www.delveinsight.com/report-store/cerebral-infarction-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" provides an in-depth analysis of cerebral infarction across the United States,
Gout Pipeline Outlook 2025: Insights Into Therapies, Research, and Market Potential
Gout Pipeline Outlook 2025: Insights Into Therapies, Research, and Market Potent …
DelveInsight's, "Gout Pipeline Insight 2025" report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Gout pipeline landscape. It covers the Gout pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Gout pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Download DelveInsight's comprehensive Gout Pipeline Report to explore emerging therapies,
Osteoporosis Pipeline Outlook 2025: Insights Into Therapies, Research, and Market Potential
Osteoporosis Pipeline Outlook 2025: Insights Into Therapies, Research, and Marke …
DelveInsight's, "Osteoporosis Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 35+ pipeline drugs in Osteoporosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Curious about the latest updates in the Osteoporosis Pipeline? Click here to explore
Oral Mucositis Pipeline Outlook 2025: Insights Into Therapies, Research, and Market Potential
Oral Mucositis Pipeline Outlook 2025: Insights Into Therapies, Research, and Mar …
DelveInsight's, "Oral Mucositis Pipeline Insight 2025" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Oral Mucositis pipeline landscape. It covers the Oral Mucositis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Oral Mucositis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Curious about the latest updates in

All 5 Releases


More Releases for Moderate

Synchronous Condenser Market Set for Moderate Growth by 2030
According to a new report published by Allied Market Research, The synchronous condenser market size was valued at $568.9 million in 2020, and is projected to reach $751 million by 2030, growing at a CAGR of 2.8% from 2021 to 2030. Synchronous condenser is the device used to generate or absorb reactive power as per the need for stabilization of electric utilities. It is an alternative to capacitor bank to correct
Tin Market Outlook: Moderate Growth Projected Through 2032
Tin Market size was valued at 282.52 Kilotonin 2024 and the total Tin revenue is expected to grow at a CAGR of 2.1% from 2025 to 2032, reaching nearly 333.63 Kiloton. Tin Market Overview: The tin market is witnessing consistent growth due to its critical applications across several industries. Tin is most commonly used in soldering, particularly within the electronics industry, which continues to expand with the rise of consumer electronics, renewable
Biocides Market Forecast Shows Moderate but Consistent Growth
Biocides market is expected to reach US$ 16.07 Bn. in 2030 from US$ 12.30 Bn. in 2023, with a CAGR of 3.9% for the period 2024-2030. Biocides Market Overview: The biocides market is experiencing steady growth, driven by increasing demand across various industries such as water treatment, healthcare, agriculture, and consumer goods. Biocides, which are chemical or biological agents that control harmful organisms, play a crucial role in ensuring hygiene, preserving materials,
Dutch Mendenhall to Moderate Athletes in Business Panel
Las Vegas, NV - July 9, 2024 - Dutch Mendenhall [https://www.linkedin.com/in/dutchmendenhall], the esteemed owner of Wentworth Golf Club [https://wentworthgolfclub.org/], best-selling author of Money Shackles, and former Division 1 volunteer coach, will moderate the "Athletes in Business" panel at The Palms Las Vegas on Sunday, July 14, 2024. This event will bring together some of the most influential athletes turned business professionals to share their insights and experiences. Dutch Mendenhall's diverse background
Planter Market will reflect a relatively moderate growth in demand
Planter is a container used for planting flowers, and different types of small plants. It can be of plastic, wood, ceramics, and glass. Planters are of different sizes, shapes, and colors. These are mostly used for decoration, nurseries, and greenhouses for both interior as well as exterior decoration. These help enhance the appearance of the property. The use of planter in decoration in hotels, rental houses can attract the customer.
Mild-to-Moderate Atopic Dermatitis Treatment Market: Lucrative Opportunities
Mild-to-moderate atopic dermatitis is a chronic inflammatory skin disease often localized to the flexural surfaces of the body and usually begins in childhood. This skin disease affects a large percentage of the world's population. Atopic dermatitis, commonly known as eczema, is characterized by dry skin, itching, redness, swelling, vesicle formation, cracking, weeping, crusting, and scaling. Atopic dermatitis is a long-term skin disease, which is classified into different types depending on